summit therapeutics astrazeneca

News

Summit, AstraZeneca and Lung cancer

Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.

Medical Dialogues · 1d

AstraZeneca, Summit in discussions over USD 15 billion cancer drug licensing deal: Report

Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a deal that could be worth up to USD 15 billion, according to a

Seeking Alpha on MSN · 2d

Summit said to be in talks with Astra to license potential rival for Merck’s Keytruda

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential rival for Merck's (MRK) Keytruda.Read more here.

2don MSN

Why Summit Therapeutics Stock Soared 8% Higher Today

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

pharmaphorum2d

Summit climbs on rumour of $15bn AstraZeneca interest

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on PD-1xVEGF bispecific ivonescimab that is estimated to be worth as much as ...

2don MSN

Why AstraZeneca Stock Got Thumped on Thursday

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

Yahoo Finance3d

Summit Therapeutics Stock Soars on Report of $15B AstraZeneca Partnership Talks - Yahoo Finance

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with AstraZeneca.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results